Clinical trial

Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.

NCT01837927

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention NVA237 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Tiotropium Respimat® Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.

Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2014-04-01

PhasePHASE3

Conditions

Pulmonary Disease, Chronic Obstructiveunresolved

Interventions

NVA237DRUG

Tiotropium Respimat®DRUG

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01837927 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.